Patrick Durez

13.5k citations
188 papers · 7.5k · 2 hit papers · h-index 39

Impact in

  • Rheumatology top 0.05%
    • Rheumatoid Arthritis Research and Therapies
    • Systemic Lupus Erythematosus Research
    • Spondyloarthritis Studies and Treatments
  • Hematology top 0.5%
    • Autoimmune and Inflammatory Disorders Research

Papers in

  • Rheumatology 146
    • Rheumatoid Arthritis Research and Therapies 135
    • Systemic Lupus Erythematosus Research 25
    • Spondyloarthritis Studies and Treatments 6
  • Hematology 24
    • Autoimmune and Inflammatory Disorders Research 20
Co-authors
Paul Emery (11 shared papers)Roy Fleischmann (17 shared papers)Stephen Hall (10 shared papers)Ronald D. Pedersen (4 shared papers)René Westhovens (33 shared papers)Andrew S. Koenig (3 shared papers)CHARLES G. PETERFY (17 shared papers)Mark C. Genovese (13 shared papers)
Journals
Annals of the Rheumatic Diseases (42 papers)Arthritis Research & Therapy (13 papers)Lara D. Veeken (11 papers)The Journal of Rheumatology (9 papers)The Lancet (6 papers)
Partner nations
BelgiumUnited StatesUnited Kingdom

In The Last Decade

Patrick Durez

182 papers receiving 7.2k citations

Patrick Durez's Hit Papers

Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III , Double‐Blind, Randomized Controlled Trial 2019 · 344 citations
3440+6+12Years since publication200400600
What are hit papers?

Paper score: A paper's citations measured against the top-1% bar of its own field and year: the square root of citations ÷ bar, so 1 means right at the bar and 2 means four times its citations. The bar blends the citation counts that enter the top 1% of the paper's subfields in its year (weighted 89.5%), of those subfields over all years (0.5%) and of its year across all fields (10%); a subfield and year with fewer than 400 papers takes its year's bar. Papers from 2026 are not scored yet: in an unfinished year, when a paper appeared matters more than how it is cited.

Hit paper: A paper cited at least 1.5× the top-1% bar of its field and year: a paper score of at least √1.5.

  1. 2019 Arthritis & Rheumatology
  2. 2008 The Lancet

Peers

Patrick Durez
Comparison fields: 5 of 125
  • Rheumatology 4.9k
  • Hematology 1.3k
  • Immunology 1.6k
  • Genetics 623
  • Radiology, Nuclear Medicine and Imaging 645
Replace Alejandro Balsa with:
Alejandro Balsa Spain
Maya H Buch United Kingdom
Xavier Le Loët France
Mahboob U. Rahman United States
THASIA G. WOODWORTH United States
Samuel H. Zwillich United States
Sriram Krishnaswami United States
David C. Gruben United States
Raimón Sanmartí Spain
Filip E Van den Bosch Belgium
Patrick Durez relative to Alejandro Balsa Spain Alejandro Balsa's profile →
Citations per field
00.5×1.5×2.1×
Alejandro Balsa · 1×
Citations per year

Countries citing papers authored by Patrick Durez

Since Specialization
Citations

This map shows the geographic impact of Patrick Durez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick Durez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick Durez more than expected).

Fields of papers citing papers by Patrick Durez

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick Durez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick Durez. The network helps show where Patrick Durez may publish in the future.

Co-authors

The 25 scholars most cited alongside Patrick Durez, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Patrick Durez Line = papers co-authored together Patrick Durez links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 188 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial
The Lancet ·Paul Emery, Ferdinand C. Breedveld, Stephen Hall, Patrick Durez, David Joey Chang, Deborah Robertson, Amitabh Singh, Ronald D. Pedersen, Andrew S. Koenig, Bruce Freundlich
Hit paper breakdown →		2008681
2
Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: Twelve‐month results of a phase iib, double‐blind, randomized, placebo‐controlled trial
Arthritis & Rheumatism ·Joel M. Kremer, Maxime Dougados, Paul Emery, Patrick Durez, Jean Sibilia, William J. Shergy, Serge Daniel Steinfeld, Elizabeth A. Tindall, Jean‐Claude Becker, Tracy M.W.Y. Li, Isaac F. Nuamah, Richard Aranda, Larry W. Moreland
2005371
3
Role of interleukin‐4 and interleukin‐10 in murine collagen‐induced arthritis. Protective effect of interleukin‐4 and interleukin‐10 treatment on cartilage destruction
Arthritis & Rheumatism ·Leo A. B. Joosten, Erik Lubberts, Patrick Durez, Monique M. A. Helsen, Marike J. M. Jacobs, Michel Goldman, Wim B. van den Berg
1997367
4
Golimumab, a human anti–tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate‐naive patients with active rheumatoid arthritis: Twenty‐four–week results of a phase III, multicenter, randomized, double‐blind, placebo‐controlled study of golimumab before methotrexate as first‐line therapy for early‐onset rheumatoid arthritis
Arthritis & Rheumatism ·Paul Emery, Roy Fleischmann, Larry W. Moreland, Elizabeth C. Hsia, Ingrid Strusberg, Patrick Durez, Peter T. Nash, Eric Amante, Melvin A. Churchill, Won Park, Bernardo Pons Estel, Mittie K. Doyle, Sudha Visvanathan, Weichun Xu, Mahboob U. Rahman
2009348
5
Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III , Double‐Blind, Randomized Controlled Trial
Arthritis & Rheumatology ·Roy Fleischmann, Aileen L. Pangan, In‐Ho Song, Eduardo Mysler, Louis Bessette, CHARLES G. PETERFY, Patrick Durez, Andrew J.K. Östör, Yihan Li, Yijie Zhou, (unknown), Mark C. Genovese
Hit paper breakdown →		2019344
6
Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial
The Lancet ·Josef S Smolen, Peter T. Nash, Patrick Durez, Stephen Hall, Elena P. Ilivanova, Fedra Irazoque-Palazuelos, Pedro Cavaleiro Miranda, Min‐Chan Park, Karel Pavelká, Ronald D. Pedersen, Annette Szumski, Constance Hammond, Andrew S. Koenig, Bonnie L. Vlahos
2013280
7
Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors
Annals of the Rheumatic Diseases ·René Westhovens, M. Robles, Antônio Carlos Ximenes, Savithree Nayiager, Jürgen Wollenhaupt, Patrick Durez, Juan Jesús Gómez-Reino, Walter Grassi, B. Haraoui, William J. Shergy, (unknown), H K Genant, CHARLES G. PETERFY, J-C Becker, A. Covucci, Roy Helfrick, Joan M. Bathon
2009270
8
Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double‐blind, placebo‐controlled, dose‐ranging study
Arthritis & Rheumatism ·Jonathan Kay, Eric L. Matteson, Bhaskar DasGupta, Peter T. Nash, Patrick Durez, Stephen Hall, Elizabeth C. Hsia, John Seungsoo Han, Carrie L. Wagner, Zhenhua Xu, Sudha Visvanathan, Mahboob U. Rahman
2008252
9
Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study
Annals of the Rheumatic Diseases ·Mark C. Genovese, Patrick Durez, Hanno B. Richards, Jerzy Supronik, Eva Dokoupilová, Mazurov Vi, Jacob A. Aelion, Sang‐Heon Lee, Christine E. Codding, Herbert L. Kellner, Takashi Ikawa, Sophie Hugot, Shephard Mpofu
2012243
10
Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial
The Lancet ·Josef S Smolen, Paul Emery, Roy Fleischmann, Ronald van Vollenhoven, Karel Pavelká, Patrick Durez, B. Guérette, H. Küpper, Laura Redden, (unknown), Arthur Kavanaugh
2013215
11
Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial)
Annals of the Rheumatic Diseases ·Paul Emery, Patrick Durez, Maxime Dougados, Clarence W. Legerton, J-C Becker, George Vratsanos, H K Genant, CHARLES G. PETERFY, P. P. Mitra, Sandra Overfield, Karen Qi, René Westhovens
2009207
12
Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis
Arthritis & Rheumatism ·D. M. van der HEIJDE, Lars Klareskog, Robert Landewé, George A. W. Bruyn, Alain G Cantagrel, Patrick Durez, Gabriel Herrero‐Beaumont, Yair Molad, Cătălin Codreanu, Gabriele Valentini, R. Zahora, Ron Pedersen, D MacPeek, Joseph S. Wajdula, Saeed Fatenejad
2007171
13
Subcutaneous abatacept versus intravenous abatacept: A phase IIIb noninferiority study in patients with an inadequate response to methotrexate
Arthritis & Rheumatism ·M. C. Genovese, A. Covarrubias, Gastón P. León, Eduardo Mysler, M. Keiserman, Robert M. Valente, Peter T. Nash, (unknown), Wieslawa Porawska, Jeffrey Box, Clarence W. Legerton, Evgeny Lvovich Nasonov, Patrick Durez, R. Aranda, R. Pappu, I. Delaet, J. Teng, Rieke Alten
2011163
14
The anti-CD20 antibody rituximab reduces the Th17 cell response
Arthritis & Rheumatism ·Frank L. van de Veerdonk, Bernard Lauwerys, Renoud J. Marijnissen, Kim Timmermans, Franco Di Padova, Marije I. Koenders, Ilse Gutierrez-Roelens, Patrick Durez, Mihai Gheorghe Netea, Jos W. M. van der Meer, Wim B. van den Berg, Leo A. B. Joosten
2011157
15
Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response
Annals of the Rheumatic Diseases ·Roy Fleischmann, Mark C. Genovese, Jeffrey Enejosa, Eduardo Mysler, Louis Bessette, CHARLES G. PETERFY, Patrick Durez, Andrew J.K. Östör, Yihan Li, In‐Ho Song
2019127
16
The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial
Annals of the Rheumatic Diseases ·Michael H. Schiff, C Pritchard, J. Eugene Huffstutter, Vicente Rodrı́guez-Valverde, Patrick Durez, Xianhuang Zhou, T Li, K Bahrt, S. Kelly, Manuela Le Bars, Mark C. Genovese
2008126
17
Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study
BMC Musculoskeletal Disorders ·Rieke Alten, Juan Jesús Gómez-Reino, Patrick Durez, André D. Beaulieu, Anthony I. Sebba, Gerhard E. Krammer, Ralph Preiss, Udayasankar Arulmani, Albert Widmer, Xavier Gitton, Herbert L. Kellner
2011126
18
Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study
Annals of the Rheumatic Diseases ·Mark C. Genovese, Roy Fleischmann, Daniel E. Furst, Namieta M. Janssen, John Carter, Bhaskar Dasgupta, Judy C. Bryson, Benjamin Duncan, Wei Zhu, Costantino Pitzalis, Patrick Durez, Kosmas Kretsos
2014125
19
Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database
Annals of the Rheumatic Diseases ·P. Taylor, T. Takeuchi, Gerd Rüdiger Burmester, Patrick Durez, Josef S Smolen, Walter G. Deberdt, M. A. A. Issa, Jorge Ross Terrés, Natalia Bello, Kevin L. Winthrop
2021121
20
In vivo induction of interleukin 10 by anti-CD3 monoclonal antibody or bacterial lipopolysaccharide: differential modulation by cyclosporin A.
The Journal of Experimental Medicine ·Patrick Durez, Daniel A. Abramowicz, Catherine M. Gerard, M Van Mechelen, Zoulikka Amraoui, Christine Dubois, Oberdan Léo, Thierry J. Velu, Michel Goldman
1993112

About Patrick Durez

Patrick Durez is a scholar working on Rheumatology, Hematology, Immunology, Genetics and Radiology, Nuclear Medicine and Imaging, having authored 188 papers that have together received 7.5k indexed citations. Recurring topics across this work include Rheumatoid Arthritis Research and Therapies (135 papers), Systemic Lupus Erythematosus Research (25 papers), Autoimmune and Inflammatory Disorders Research (20 papers), Monoclonal and Polyclonal Antibodies Research (16 papers), Chronic Lymphocytic Leukemia Research (12 papers), Biosimilars and Bioanalytical Methods (10 papers), Lymphoma Diagnosis and Treatment (9 papers) and Spondyloarthritis Studies and Treatments (6 papers). The work is most often cited by research in Rheumatology (4.9k citations), Hematology (1.3k citations), Immunology (1.6k citations), Genetics (623 citations) and Radiology, Nuclear Medicine and Imaging (645 citations). Patrick Durez has collaborated with scholars based in Belgium, United States and United Kingdom. Frequent co-authors include Paul Emery, Roy Fleischmann, Stephen Hall, Ronald D. Pedersen, René Westhovens, Andrew S. Koenig, CHARLES G. PETERFY, Mark C. Genovese, Peter T. Nash and Deborah Robertson. Their work appears in journals such as Annals of the Rheumatic Diseases, Arthritis Research & Therapy, Lara D. Veeken, The Journal of Rheumatology and The Lancet.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alejandro BalsaBreakdown of academic impact, for papers by Maya H BuchBreakdown of academic impact, for papers by Xavier Le LoëtBreakdown of academic impact, for papers by Mahboob U. RahmanBreakdown of academic impact, for papers by THASIA G. WOODWORTHBreakdown of academic impact, for papers by Samuel H. ZwillichBreakdown of academic impact, for papers by Sriram KrishnaswamiBreakdown of academic impact, for papers by David C. GrubenBreakdown of academic impact, for papers by Raimón SanmartíBreakdown of academic impact, for papers by Filip E Van den Bosch